* PALUMED *
2000 - Midi-Pyrénées
Toulouse
www.palumed.com Discovery, Drugs
Key words: Anti-malarial, Antibacterial, Covalent bi-therapy, Trioxaquines
Mission: to develop new antimalarial agents and also new antibacterial molecules and chelating agents for the treatment of neurodegenerative diseases
Clients: Pharmaceutical industry (Sanofi-Aventis)
info@palumed.fr
Age: 16 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Meunier (Bernard) [born 1947, ex-Polytechnique (Professor), CNRS (President)]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Meunier-Chesny (Claudine) [born 1949]
Financers (Hist.): IRDI, SOCRI, FCJE (CDC), GSO Capital, Viveris | Turnover (M€) : 0.29 (2009), 0.59 (2007), 0.23 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Infections
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2009 .06 | Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Serial Genetics, Genewave, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) | DEBT | [8 years] |
| 2008 .05 | Patent : pending on 3rd generation Trioxaquines with Sanofi-Aventis | LEGAL | [7 years] |
| 2006 .02 | Nomination : Bernard Meunier as CEO, replacing Claudine Meunier-Chesny (moving to Alliances Dir.) | ORGN | [5 years] |
| 2002 .07 | 1st round-financing : undisclosed M€, by IRDI, SOCRI, FCJE (CDC), GSO Capital, followed by Viveris (2005) | RFINA | [1 year] |
| 2000 .12 | Company founded by Bernard Meunier and Claudine Meunier-Chesny | ORGF | [0 year] | Actualisation / Updating: 9-May-2011 |
|
